AVXL — ANAVEX LIFE SCIENCES CORP.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1314052 ·
Last close
$1.54
Market Cap
$142.75M
52W High
$9.95
52W Low
$1.50
ADV30
1,002,509
Next earnings
2026-11-24
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | 6,771,000 | 7,824,000 | 120,139,000 | 118,326,000 | 7,692,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -6,782,000 | -5,681,000 | 132,989,000 | 131,749,000 | 6,371,000 |
| Sep 2025 | 0 | — | -11,479,000 | -9,827,000 | 103,815,000 | 102,577,000 | 8,946,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,075,000
Investing CF
—
Financing CF
$45,049,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.39
As of
2026-08-30
Balance + Analyst (yfinance extras)
Retained Earnings
$-388,129,000
Inventory
—
Receivables
$844,000
ST Investments
—
EBIT TTM
$-39,991,000
Pretax Income TTM
$-39,929,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -51,371,000 | -46,377,000 | 103,815,000 | 8,946,000 | 94,869,000 | -39,044,000 |
| Sep 2024 | 0 | -52,802,000 | -43,002,000 | 135,567,000 | 15,304,000 | 120,263,000 | -30,812,000 |
| Sep 2023 | 0 | -55,738,000 | -47,505,000 | 154,386,000 | 12,534,000 | 141,852,000 | -27,785,000 |
| Sep 2022 | 0 | -50,986,000 | -47,978,000 | 152,705,000 | 10,214,000 | 142,491,000 | -24,238,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-39,947,000
OpCashFlow TTM
—
Assets (Latest)
$132,989,000
Forward EPS
$-0.55
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.46 · call volume: 4 · put volume: 40
Expected Move to 2026-10-16:
±$0.58
(39.52%) —
implied range
$0.88 –
$2.03
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | $143.52M | $3.86 | — |
| MOLN | MOLECULAR PARTNERS AG | $145.94M | $3.81 | — |
| VYGR | Voyager Therapeutics, Inc. | $146.03M | $2.37 | — |
| OTLK | Outlook Therapeutics, Inc. | $137.30M | $0.56 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $151.87M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
2026-09-24 14:00 · Yahoo
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
2026-09-18 13:48 · Yahoo
PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
2026-09-14 23:30 · Yahoo
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
2026-09-10 18:45 · Yahoo
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
2026-09-08 12:00 · Yahoo
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
2026-09-03 21:46 · Yahoo
PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting
2026-09-01 21:35 · Yahoo
Anavex Life Sciences Advances Alzheimer’s Phase 3 Planning as Cash Runway Extends Into Fiscal 2028
2026-08-25 14:46 · Yahoo
Anavex Urges Shareholders to Back Six Director Nominees Ahead of 2026 Annual Meeting
2026-08-17 15:04 · Yahoo
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
2026-08-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.